Ticker Details
Viking Therapeutics, Inc. Viking Therapeutics Inc is a clinical-stage biopharmaceutical company. The company develops therapies for metabolic and endocrine disorders. It includes portfolio of five drug candidates in clinical trials or preclinical studies.
IPO Date:	April 29, 2015
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$4.78B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.56 | 3.78%
Avg Daily Range (30 D):	$1.07 | 3.22%
Avg Daily Range (90 D):	$0.96 | 2.92%

Institutional Daily Volume
Avg Daily Volume:	1.88M
Avg Daily Volume (30 D):	2.34M
Avg Daily Volume (90 D):	2.14M

Trade Size
Avg Trade Size (Sh.):	112
Avg Trade Size (Sh.) (30 D):	74
Avg Trade Size (Sh.) (90 D):	72

Institutional Trades
Total Institutional Trades:	5,370
Avg Institutional Trade:	$2.75M
Avg Institutional Trade (30 D):	$3.13M
Avg Institutional Trade (90 D):	$3M
Avg Institutional Trade Volume:	.1M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$6.49M
Avg Closing Trade (30 D):	$9.62M
Avg Closing Trade (90 D):	$8.02M
Avg Closing Volume:	247.88K

News

Jul 8, 2026 @ 6:10 PM Is It Too Late to Buy Eli Lilly? Source: Adria Cimino

Jul 6, 2026 @ 11:35 AM CRISPR Therapeutics vs. Viking Therapeutics: Which... Source: Erin Kennedy

Jul 6, 2026 @ 11:15 AM Could This Healthcare Stock Help You Build a Real ... Source: Lee Samaha

Jul 5, 2026 @ 5:05 AM How Much Could $1,000 Invested in Viking Therapeut... Source: Alex Carchidi

Jul 4, 2026 @ 9:10 AM Is Viking Therapeutics Stock Going to $50? Here's ... Source: Adria Cimino

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-3.19	$-1.39	$-3.19
Diluted EPS	$-3.19	$-1.39	$-3.19
Revenue	$M	$M	$M
Gross Profit
Net Income / Loss	$-359.64M	$-157.66M	$-359.64M
Operating Income / Loss	$-393.34M	$-164.74M	$-393.34M
Cost of Revenue
Net Cash Flow	$139.14M	$65.43M	$139.14M
PE Ratio